Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
IQVIA Holdings Inc. (IQV) is a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, including pharmaceutical, biotechnology, medical device, and healthcare stakeholders. The company operates at the intersection of healthcare data, technology, and scientific expertise, supporting the development, commercialization, and optimization of medical treatments across the product lifecycle.
IQVIA’s primary revenue drivers are its Technology & Analytics Solutions and Research & Development Solutions segments, which together deliver data-driven insights, real-world evidence, clinical trial execution, and commercial analytics. The company serves large and mid-sized pharmaceutical companies, emerging biotech firms, contract research organizations, healthcare providers, and regulators. IQVIA’s strategic advantage lies in its scale of proprietary healthcare data, integrated analytics platforms, and global clinical trial infrastructure. The company was formed in 2016 through the merger of IMS Health and Quintiles, combining commercial healthcare intelligence with clinical research capabilities into a single integrated platform.
Business Operations
IQVIA operates through two primary business segments: Technology & Analytics Solutions (TAS) and Research & Development Solutions (R&DS). Technology & Analytics Solutions provides data assets, analytics, cloud-based platforms, and consulting services that help clients understand disease patterns, patient outcomes, market dynamics, and commercial performance. Revenue in this segment is driven by long-term data subscriptions, software platforms, and analytics services.
Research & Development Solutions focuses on outsourced clinical research services, including clinical trial design, site management, patient recruitment, data management, and regulatory support. This segment generates revenue primarily through multi-year service contracts with life sciences companies. IQVIA operates globally, leveraging proprietary technologies, centralized laboratories, and decentralized trial capabilities. The company maintains numerous subsidiaries worldwide, reflecting its integrated operating model rather than stand-alone joint ventures, and collaborates with healthcare systems, academic institutions, and technology partners to enhance trial efficiency and data quality.
Strategic Position & Investments
IQVIA’s strategy emphasizes long-term growth through data scale expansion, technology innovation, and deeper integration across the healthcare ecosystem. Key initiatives include advancing real-world evidence capabilities, expanding decentralized and hybrid clinical trials, and applying artificial intelligence and machine learning to clinical and commercial decision-making. These initiatives are designed to reduce development timelines, improve patient access, and enhance regulatory and payer engagement.
The company has pursued selective acquisitions to strengthen its analytics, digital health, and clinical trial technologies, integrating acquired capabilities into its core platforms rather than operating them as independent entities. IQVIA continues to invest in cloud-based infrastructure, privacy-compliant data aggregation, and advanced analytics tools, positioning itself as a critical partner for life sciences companies navigating increasingly complex regulatory, scientific, and commercial environments.
Geographic Footprint
IQVIA is headquartered in North America, with its corporate headquarters located in Durham, North Carolina, United States. The company maintains a significant operational presence across North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa, supporting clients in more than 100 countries.
Its global footprint enables IQVIA to conduct multinational clinical trials, aggregate healthcare data from diverse markets, and deliver localized regulatory and commercial expertise. International operations represent a substantial portion of revenue, reflecting the company’s role as a global partner to multinational life sciences organizations and regional healthcare innovators.
Leadership & Governance
IQVIA is led by an executive team with deep experience in healthcare, data science, and global operations. The leadership emphasizes a strategy centered on scientific rigor, data integrity, technological innovation, and ethical use of healthcare data to improve patient outcomes and system efficiency.
Key executives include:
- Ari Bousbib – Chairman and Chief Executive Officer
- Kalyani Sekar – Chief Financial Officer
- Bhavik Patel – President, Research & Development Solutions
- Stacey Linnartz – President, Technology & Analytics Solutions
- Michael J. Hennessy Jr. – Chief Operating Officer
The company operates under a governance framework aligned with public company standards, with oversight from an independent board of directors and a focus on compliance, data privacy, and long-term shareholder value creation.